在阿尔茨海默氏病的细胞外囊泡
Victor Hugo Berriel Pinho1, João Paulo Lima Daher2, Salim Kanaan2
1Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro RJ, Brazil.
Arquivos de neuro-psiquiatria
|March 11, 2024
概括
细胞外囊泡 (EVs) 显示出作为阿尔茨海默病 (AD) 生物标志物的前景. 神经元衍生的EVs含有AD蛋白质,如粉样β,有助于早期诊断和监测.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 细胞外囊泡 (EVs) 在中枢神经系统 (CNS) 中调解细胞信号.
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,涉及认知能力下降和神经元死亡.
- EVs与正常的中枢神经系统功能和AD病变发生有关.
研究的目的:
- 研究EVs作为阿尔茨海默病 (AD) 潜在生物标志物的作用.
- 在AD病理学背景下分析EVs的组成.
- 探索在AD中EVs的诊断和监测潜力.
主要方法:
- 在AD.中分析来自神经元,星体细胞和神经元前体细胞的EVs.
- 在神经元衍生的EV中检测AD相关蛋白质,包括粉样β (Aß) 和tau.
- 从血样本中分离和量化来自神经元的EVs.
主要成果:
- 来自各种中枢神经系统细胞类型的EV在AD中显示出改变的数量和组成.
- 神经元衍生的EVs含有关键的AD蛋白质,如粉样蛋白β (Aß) 和tau.
- 血衍生的神经元衍生的EV中Aß水平升高与AD和轻度认知障碍相关,表明早期生物标志物的潜力.
结论:
- EVs,特别是来自神经元的EVs,显示出作为早期AD诊断和疾病进展监测的生物标志物的巨大潜力.
- 需要进一步的研究来验证基于电动汽车的生物标志物,并探索治疗应用.
- 电动汽车是了解和管理阿尔茨海默病的有希望的途径.
更多相关视频
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
421
10:09Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
Published on: June 2, 2020
6.9K
相关概念视频
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Role of Neurotransmitters in Memory
549
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
549
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Intralumenal Vesicles and Multivesicular Bodies
3.5K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.5K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
